Amesite (NASDAQ:AMST) held its 2026 annual stockholders meeting virtually on July 13, with Founder and CEO Dr. Ann Marie Sastry presiding and outlining recent developments in the company’s healthcare-focused artificial intelligence business.
The formal portion of the meeting included the presentation of four stockholder proposals, all of which were approved based on preliminary voting results. Sean Reid of Sheppard, Mullin, Richter & Hampton LLP, the company’s outside counsel and secretary of the meeting, said final voting results would be reported in a Form 8-K filing within four business days.
Stockholders Approve Board, Auditor and Equity Plan Items
The approved proposals included:
- The election of two Class II directors to serve three-year terms or until their successors are elected and qualified.
- The ratification of Novogradac & Company LLP as the company’s independent registered public accounting firm for the fiscal year ending June 30, 2026.
- An amendment to the company’s 2018 Equity Incentive Plan to increase the number of shares available for issuance by 1 million shares and increase the number of shares that may be issued through incentive stock options by 1 million shares.
- Approval under Nasdaq Listing Rule 5635(d) for the issuance of shares of common stock upon exercise of the company’s Series A-1 and Series A-2 warrants.
Dr. Sastry also introduced members of the board present at the meeting, including J. Michael Losh, Gilbert S. Omenn, Barbie Brewer and George Parmer. Sarah Berman, Amesite’s principal financial and accounting officer, served as inspector of elections.
CEO Highlights Healthcare AI Strategy
After the formal meeting was adjourned, Dr. Sastry provided a brief business update, saying Amesite has had “an exciting two years” since entering the healthcare space with NurseMagic. She said the product initially entered the market as a business-to-consumer offering before expanding into business-to-business customers.
Dr. Sastry said Amesite recently announced the addition of a “large census customer” after growing and broadening its customer base to include several care settings in the post-acute market. She described post-acute care as “growing at the fastest CAGR of anything in the healthcare sector” and said the company was pleased to show its ability to scale.
Company Sees Greater Growth in B2B
During the question-and-answer session, Amesite was asked where it expects more growth: B2C or B2B. Dr. Sastry said the company anticipates greater growth in B2B as it seeks to become “an AI layer” for businesses providing post-acute care in the United States.
She said businesses in the sector “crucially need AI layers in order to become more efficient,” adding that Amesite aims to serve multiple customers in the B2B space.
Amesite Describes AI Model Approach
In response to a question about whether Amesite views AI models as a strategic advantage, Dr. Sastry said the company has long believed AI models will become “scaled and more or less commoditized.” She said Amesite’s value lies in implementing models effectively and deploying the right model at the right time, whether commercially sourced or developed internally.
Dr. Sastry said selecting and deploying AI models on “secure, stable, scalable infrastructure” requires expertise, and said Amesite’s engineering, mathematics and business capabilities help it deliver solutions to companies that need them to improve healthcare delivery and remain competitive.
CEO Says Large Customer Win Is Repeatable
Amesite was also asked whether its recently announced large customer win is repeatable. Dr. Sastry said the company believes it is, pointing to its earlier B2C experience with nurses and its move into B2B deployments.
She said documentation consumes roughly 40% of healthcare workers’ time and argued that AI tools must help users submit documentation in a timely way while also being tools they want to use. Dr. Sastry said Amesite’s B2B offering can function as an overlay to existing technology stacks, allowing customers to adopt AI tools without replacing existing systems.
“Yes, we do believe strongly that this is repeatable because we did the reps, and we did the pieces of the technology to show how it works,” Dr. Sastry said.
About Amesite (NASDAQ:AMST)
Amesite, Inc (NASDAQ: AMST) is a software company specializing in AI-driven digital learning and training solutions. Its cloud-based platform enables organizations to create, manage and deliver customized online courses and professional development programs. Leveraging machine learning and natural language processing, the platform offers real-time analytics, adaptive content recommendations, multimedia assessments and community collaboration tools to support both synchronous and asynchronous learning.
The company’s primary end markets include corporate enterprises, higher education institutions, government agencies and nonprofit organizations.
